Prioritise targets that matter
A comprehensive view of tumour biology to identify and advance neoantigen targets.
Technology
ONVAC™ Platform: From tumour data to manufacturing-ready cancer vaccines.
ONVAC™ is Oncocine's AI-native platform for adaptive cancer vaccine development. It transforms complex tumour and immune microenvironment data into manufacturing-ready mRNA vaccine designs.
By connecting tumour biology to vaccine design, ONVAC™ ensures superior target selection and patient stratification in one end-to-end system, helping reduce the time, cost, and risk of taking cancer vaccine programmes from data to clinic.
Turn tumour complexity into vaccine programmes built to move faster.
ONVAC™ turns tumour and immune microenvironment data into actionable vaccine designs, from target selection to manufacturing-ready mRNA.
De-risk programmes earlier
Identify immune and tumour-context risks before they lead to avoidable delays, redesigns, or poorly matched development strategies.
Combination approaches
Explore combination strategies with our cancer vaccines to boost immune responses.
Adaptable vaccine programmes
Enable personalised and off-the-shelf vaccine opportunities across tumour types.
Why ONVAC™
Tumour intelligence beyond target prediction
ONVAC™ combines neoantigen discovery with tumour microenvironment and clonality intelligence, enabling vaccine design decisions that account for both tumour targets and the immune context they must overcome.
Manufacturing-ready designs
ONVAC™ brings modular, codon-optimised mRNA design into a single end-to-end workflow, rather than relying on months of manual optimisation.
A platform that compounds with every programme
Each patient and programme adds to a growing foundation of tumour, antigen, and design intelligence, expanding the potential for both personalised and off-the-shelf vaccine assets over time.
Frequently Asked Questions
Build the future of cancer vaccines with us.
Oncocine is seeking pharma, biotech, and strategic partners to develop the next generation of adaptive cancer vaccines, and investors who share our ambition to expand cancer vaccines across several tumour types.
Connect with our team